Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.64−0.02 (-3.31%)
Close on Nov 11, 2026Market cap $252.43MP/E 2.9Yield –
Standard BioTools ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Standard BioTools's ebitda for the twelve months ending Jun 30, 2026 was -$89.97M. For fiscal 2025 it was -$100.99M. The highest annual figure on record is -$13.43M in fiscal 2010.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$100.99M | – |
| FY2024 | Dec 31, 2024 | -$114.97M | – |
| FY2023 | Dec 31, 2023 | -$72.62M | – |
| FY2022 | Dec 31, 2022 | -$112.71M | – |
| FY2021 | Dec 31, 2021 | -$64.24M | – |
| FY2020 | Dec 31, 2020 | -$47.02M | – |
| FY2019 | Dec 31, 2019 | -$47.23M | – |
| FY2018 | Dec 31, 2018 | -$42.79M | – |
| FY2017 | Dec 31, 2017 | -$50.95M | – |
| FY2016 | Dec 31, 2016 | -$66.45M | – |
| FY2015 | Dec 31, 2015 | -$45.24M | – |
| FY2014 | Dec 31, 2014 | -$47.78M | – |
| FY2013 | Dec 31, 2013 | -$16.10M | – |
| FY2012 | Dec 31, 2012 | -$15.88M | – |
| FY2011 | Dec 31, 2011 | -$17.16M | – |
| FY2010 | Dec 31, 2010 | -$13.43M | – |
| FY2009 | Dec 31, 2009 | -$16.41M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$24.12M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.35M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.42M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.52M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$22.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.41M | – |
| Q1 FY2024 | Mar 31, 2024 | -$57.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.68M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.19M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.93M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.29M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.23M | – |
| Q2 FY2022 | Jun 30, 2022 | -$37.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.35M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.39M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.88M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.85M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.06M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.68M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.48M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.02M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.87M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.44M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.84M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.65M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.90M | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.11M | – |
| Q2 FY2017 | Jun 30, 2017 | -$14.35M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.59M | – |
| Q4 FY2016 | Dec 31, 2016 | -$15.93M | – |
| Q3 FY2016 | Sep 30, 2016 | -$16.76M | – |
See a number that looks wrong?